Dyslipidaemia and diabetes mellitus;Dyslipidémie et diabète

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 578-585

  Ducobu, J ^a  

^a Centre Hospitalier Universitaire de Tivoli   (Belgium)

Author keywords

Diabetes; Dyslipidaemia; Fibrates; Statins

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; EVALUATION; HUMAN; LIFESTYLE; METABOLIC SYNDROME X; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

CLOFIBRIC ACID; DIABETES COMPLICATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIFE STYLE; RISK FACTORS;

EID: 21744449785     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Haffner SM, Lehto S, Ronnemaa T et al.- Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998, 339, 229-234.
2. The DCCT Research Group.- Lipid and lipoprotein levels in patients with IDDM Diabetes Control and Complications Trial experience. Diabetes Care, 1992, 15, 886-894
3. Taskinen MR.- Insulin resistance and lipoprotein metabolism. Curr Opin Lipidol, 1995, 6, 153-160.
4. Taskinen MR.- Diabetic dyslipidemia. Diabetologia, 2003, 46, 733-749.
5. Haffner SM.- Lipoprotein(a) and diabetes. An update. Diabetes Care, 1993, 16, 835-840.
6. Reaven GM.- Non-insulin-dependent diabetes mellitus, abnormal lipoprotein metabolism, and atherosclerosis. Metabolism, 1987, 36, 1-8.
7. Debacker G.- European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiov Prev Rehab, 2003, 10, S1-S78.
8. Belgian Lipid Club.- Recommandations pour le diagnostic et le traitement des dyslipidémies (Guide de oche) - 4ème édition, 2004.
9. Scheen AJ.- Comment j'explore ... Le risque cardiovasculaire absolu à 10 ans: de Framingham 1998 à SCORE 2003. Rev Med Liège, 2004, 59, 460-466.
10. De Backer G, De Bacquer D, Brohet C, et al.- Recommandations relatives àla prévention des maladies cardio-vasculaires en pratique clinique: Groupe de Travail Belge de Prévention des Maladies Cardio-Vasculaires. Rev Med Liège, 2005, 60, 163-172.
11. American Diabetes Association.- Dyslipidemia management in adults with diabetes. Diabetes Care, 2004, 27 Suppl 1, S58-S68.
12. Ducobu J.- HDL, Syndrome polymétabolique et fibrates. J Cardiol, 2004, 16, 170-178.
13. Sacks FM, Pfeffer MA, Moye LA et al.- The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996, 335, 1001-1009.
14. Scandinavian Simvastatin Survival Study Group.-Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344, 1383-1389.
15. Heart Protection Study Collaborative Group.-MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 2003, 361, 2005-2016.
16. Colhoun HM, Betteridge DJ, Durrington PN, et al.-Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364, 685-696.
17. Rubins HB, Robins SJ, Collins D, et al.- Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med, 1999, 341, 410-418.
18. Robins SJ, Rubins HB, Pass FH, et al.- Insulin resistance and cardiovascular events with low HDL-cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care, 2003, 26, 1513-1517.
19. Frick MH, Elo O, Haapa K et al.- Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med, 1987, 317, 1237-1245.
20. The Bip Study Group.- Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation, 2000, 102, 21-27.
21. Fruchart JC, Duriez P, Saels B.- Peroxisome proliferators-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol, 1999, 10, 245-257.
22. Robins SJ.- Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Curr Opin Lipidol, 2003, 14, 575-583.
23. Vijan S, Hayward RA.- Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med, 2004, 140, 650-658.
24. Grundy SM, Vega GL, McGovern ME et al.- Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med, 2002, 162, 1568-1576.
25. Zhao XQ, Morse JS, Dowdy AA et al.- Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol, 2004, 93, 307-312.
26. Joslin EP.- Arteriosclerosis and diabetes. Ann Clin Med, 1927, 5, 1061-1079.